Munia Marco Antonio, Munia Christine Guarnieri, Parada Meire Brasil, Ben-Hurferraz Parente Jose, Wolosker Nelson
All authors are with Hospital Moriah in São Paulo, Brazil.
J Clin Aesthet Dermatol. 2022 Feb;15(2):40-43.
Facial injections with hyaluronic acid (HA) dermal fillers have become increasingly common. Hyaluronic acid is currently the most frequently used dermal filler. When compared to collagen for the treatment of nasolabial folds, HA not only produces similar cosmetic results with smaller doses but also lasts longer. Our objective was to evaluate the results of 10 patients with vascular complications associated with HA fillers treated with ultrasound-guided injection of hyaluronidase (HYAL) according to the Brazilian Society of Dermatology guidelines. Admission clinical evaluation revealed that the most frequent signs were: livedo reticularis (100% of the patients), hypoesthesia (50%) and local pain (20%). Although 80% of the patients complained of local pain during HYAL injection, none of them persisted with pain after the procedure ended. The total dose of injected HYAL per patient ranged from 300 to 750 IU (mean 500 IU). Post-HYAL treatment Doppler ultrasound showed pervious facial arteries and veins in 100% of the patients.
使用透明质酸(HA)真皮填充剂进行面部注射已变得越来越普遍。透明质酸是目前最常用的真皮填充剂。与胶原蛋白用于治疗鼻唇沟相比,透明质酸不仅以较小剂量产生相似的美容效果,而且持续时间更长。我们的目的是根据巴西皮肤病学会指南,评估10例与HA填充剂相关的血管并发症患者接受超声引导下注射透明质酸酶(HYAL)的治疗结果。入院临床评估显示,最常见的体征为:网状青斑(100%的患者)、感觉减退(50%)和局部疼痛(20%)。尽管80%的患者在注射HYAL时抱怨局部疼痛,但在操作结束后均无疼痛持续。每位患者注射的HYAL总剂量为300至750国际单位(平均500国际单位)。HYAL治疗后的多普勒超声显示100%的患者面部动脉和静脉通畅。